Drug Profile
Bupropion - Biovail Corporation
Alternative Names: 323U66; Amfebutamone; Amfebutamone SR; Aplenzin; Bupropion HCL SR; Bupropion hydrobromide; Bupropion hydrochloride; Bupropion hydrochloride SR; Bupropion XL; BVF 033; Elontril; Quomem; Wellbutrin; Wellbutrin SR; Wellbutrin XL; Wellbutrin XR; ZybanLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Biovail Corporation
- Developer Bausch Health Companies; GSK
- Class Antidepressants; Obesity therapies; Propiophenones; Small molecules; Smoking cessation therapies
- Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Major depressive disorder; Seasonal affective disorder; Smoking withdrawal
- No development reported Obesity; Post-traumatic stress disorders; Social phobia
Most Recent Events
- 24 May 2021 Boehringer Ingelheim plans a phase I pharmacokinetic trial in healthy volunteers (PO) in June 2021 (NCT04899674)
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 17 Mar 2017 GlaxoSmithKline completes a phase III trial in Major Depressive Disorder in China (NCT02191397)